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Objective  To investigate and demonstrate persistent increase of peak cough flow after mechanical in-exsufflator 
application, in patients with neuromuscular diseases and pneumonia. 
Methods  A mechanical in-exsufflator was applied with patients in an upright or semi-upright sitting position 
(pressure setting, +40 and −40 cmH2O; in-exsufflation times, 2–3 and 1–2 seconds, respectively). Patients 
underwent five cycles, with 20–30 second intervals to prevent hyperventilation. Peak cough flow without and with 
assistive maneuvers, was evaluated before, and 15 and 45 minutes after mechanical in-exsufflator application.
Results  Peak cough flow was 92.6 L/min at baseline, and 100.4 and 100.7 L/min at 15 and 45 minutes after 
mechanical in-exsufflator application, respectively. Assisted peak cough flow at baseline, 15 minutes, and 45 
minutes after mechanical in-exsufflator application was 170.7, 179.3, and 184.1 L/min, respectively. While peak 
cough flow and assisted peak cough flow increased significantly at 15 minutes after mechanical in-exsufflator 
application compared with baseline (p=0.030 and p=0.016), no statistical difference was observed between 15 and 
45 minutes.
Conclusion  Increased peak cough flow after mechanical in-exsufflator application persists for at least 45 minutes.
Keywords  Mechanical in-exsufflator, Neuromuscular diseases, Pneumonia, Peak cough flow
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INTRODUCTION
Respiratory infection is the most common cause of hos-
pitalization, in patients with neuromuscular diseases [1]. 
Especially, in patients with amyotrophic lateral sclerosis 
(ALS), respiratory complications due to excessive airway 
secretions and ineffective coughing, are principal causes 
of morbidity and mortality [2-4]. Among patients with 
Duchenne muscular dystrophy, 90% die of respiratory 
complications [5-7]. Thus, it is important to effectively 
remove airway secretions in patients with neuromuscular 
diseases, who have respiratory muscle weakness.
Effectiveness of the removal of airway secretions, de-
pends on peak cough flow (PCF). According to previous 
studies, a PCF value of at least 160 L/min is needed for 
effective removal of airway secretions [1,8,9].
A mechanical in-exsufflator (MI-E) is used in patients 
with neuromuscular disease, with reduced PCF to re-
move airway secretions. By alternately applying posi-
tive and negative pressure to the airway, MI-E is used to 
remove secretions in the airway. This can be effectively 
used for removal of secretions in patients with respiratory 
infections with excessive sputum, as well as in patients 
with neuromuscular diseases showing decreased ability 
to voluntarily cough [10].
Previous studies have shown that PCF increases, during 
or immediately after MI-E application, in patients with 
neuromuscular diseases [10-13]. However, it is unknown 
whether increased PCF persists for a certain period, after 
application of MI-E. Therefore, in addition to investigat-
ing effects of MI-E, this study examined changes in PCF 
before and after a certain period, from application of 
MI-E in patients with neuromuscular diseases who have 
pneumonia and difficulty in voluntarily expelling sputum 
because of weakened respiratory muscles.
MATERIALS AND METHODS
Subjects
This study was conducted on subjects with neuromus-
cular diseases with pneumonia admitted to a university 
hospital from August 2015 to July 2016. Pneumonia was 
diagnosed based on clinical symptoms, and laboratory 
and radiologic findings. Evidence of cardinal infec-
tion such as fever or chills and leukocytosis, signs or 
symptoms localized to the respiratory system (cough, 
increased sputum production, and increased respiratory 
rates), and a new or changed infiltrate on simple radiog-
raphy were analyzed. All patients enrolled in the study 
received intravenous antibiotics therapy, for treatment of 
pneumonia, and the study was conducted during treat-
ment.
The following patients were excluded: those with a risk 
for barotrauma and a history of pneumothorax or lung 
bullae; those in whom PCF could not be checked because 
of severe bulbar dysfunction; those who need continuous 
ventilator support, and could not perform the test; and 
those who showed unstable vital signs. We did not ex-
clude pediatric patients; however, we excluded patients 
with impaired cognitive function.
Study protocol
We applied the MI-E to patients according to protocol of 
our institute, based on cumulative experiences and other 
previous research. During the application, patients were 
in an upright or semi-upright sitting position. Settings of 
the MI-E were +40 cmH2O and -40 cmH2O pressure with 
insufflation and exsufflation times of 2–3 and 1–2 sec-
onds, respectively [13]. Patients underwent a total of five 
cycles, with a pause of 20–30 seconds between each cycle 
to prevent hyperventilation [14].
PCF without assistance and assistive PCF (APCF) were 
evaluated sequentially as follow: PCF and APCF before 
MI-E application, PCF and APCF 15 minutes after MI-E, 
and PCF and APCF 45 minutes after MI-E. Non-assisted 
PCF was measured by asking the patient to inhale maxi-
mum amount of air unassisted, before coughing as hard 
as possible. APCF was measured by first asking the 
patient to inhale maximum amount of air unassisted, 
breathing in additional amount of air through a mask by 
using a manual resuscitator bag, and then an assistant 
applied a strong push to the patient’s abdomen while the 
patient was coughing [10]. Each process was repeated at 
least three times, and maximum value was selected from 
measurements (Fig. 1). Protocol was approved by the In-
stitutional Review Board of Gangnam Severance Hospital 
(No. 3-2015-0149).
Statistical analysis was performed using IBM SPSS sta-
tistics version 20 (IBM, Armonk, NY, USA). Repeated-
measures analysis of variance was used to compare 
values of PCF and APCF at each time, with Bonferroni 
correction for post hoc analysis.
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RESULTS
A total of 27 patients (11 with Duchenne muscular dys-
trophy, 10 with progressive muscular dystrophy, 3 with 
ALS, 2 with spinal muscular atrophy, and 1 with limb-
girdle muscular dystrophy) were included. Mean age 
was 30.0±13.3 years (range, 12–66 years), and 21 of them 
(77.8%) were men. All patients had a functional disability 
and could not walk without support. Twenty-four of them 
were using non-invasive ventilator support, and none of 
them was using invasive ventilator support (Table 1).
In baseline evaluation before application of MI-E, ini-
tial PCF value was 92.6±57.1 L/min and the APCF value 
was 170.7±66.0 L/min. At 15 minutes after application 
of MI-E, measured PCF was 100.4±57.2 L/min and the 
APCF was 179.3±12.4 L/min. At 45 minutes later, PCF was 
100.7±60.9 L/min and the APCF was 184.1±75.5 L/min. 
The increase in PCF and that in APCF compared with 
their baseline values, were both statistically significant 
(p=0.001). Comparing baseline PCF and APCF with mea-
Table 1. Baseline characteristics of patients
Characteristic Value
Age (yr) 30.0±13.3
Sex
   Male 21
   Female 6
Use of non-invasive ventilator 24 (82.8)
Respiratory parameters 
   FVC (mL) 652.4±296.6
   FVC (% of predicted value) 16.6±8.9
   MIP (cmH2O) 16.6±9.4
   MIP (% of predicted value) 19.7±13.4
   MEP (cmH2O) 19.2±12.7
   MEP (% of predicted value) 16.3±13.5
Values are presented as mean±standard deviation or num-
ber (%).
FVC, forced vital capacity; MIP, maximal inspiratory pres-
sure; MEP, maximal expiratory pressure. 
Table 2. Measured PCF according to time
Before 15 min 45 min p-valuea)
Post-hoc analysis (p-value)
Before vs. 15 min 15 min vs. 45 min
PCF (L/min) 92.6±11.0 100.4±11.0 100.7±11.7 <0.001 0.030 >0.999
APCF (L/min) 170.7±12.7 179.3±12.9 184.1±14.5 <0.001 0.016 0.158
Values are presented as mean±standard error.
PCF, peak cough flow; APCF, assisted peak cough flow.
a)Repeated-measure ANOVA.
A
0 15 30
120
110
100
90
80
45
P
C
F
Time (min)
70
p<0.001
p=0.03
0 15 30
210
200
190
180
160
45
A
P
C
F
Time (min)
150
p<0.001
p=0.016
170
B
Fig. 1. (A) PCF and (B) APCF before and after mechanical in-exsufflator application. Each graph shows the mean (dot) 
and standard error (bar). PCF, peak cough flow; APCF, assisted peak cough flow.
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sured value after 15 minutes, a statistically significant dif-
ference was found for both parameters (p=0.03, p=0.016). 
However, comparing PCF and APCF values measured 
after 15 minutes with those measured after 45 minutes, 
peak flow was increased but the difference between time 
points was not statistically significant (Table 2, Fig. 1). 
DISCUSSION
This study demonstrated that PCF and APCF increase 
for a certain period, after use of MI-E in patients with 
neuromuscular disease and pneumonia. According to 
previous studies, compared with unassisted coughing 
and other standard cough augmentation techniques 
(physiotherapy-assisted, non-invasive ventilator-assist-
ed, and exsufflation-assisted coughing), the MI-E sig-
nificantly increased PCF in patients with neuromuscular 
disease [10-13]. However, although existing studies have 
demonstrated increase in PCF during or immediately af-
ter use of MI-E, none of the studies showed whether the 
effects persist for a certain period. This study is the first 
to demonstrate increased PCF even after a certain period 
after application.
Maintaining increased cough flow is more critical in 
patients treated for current respiratory infection, because 
all of them have coughing disability and trouble with 
eliminating secretion. Nonetheless, whereas many previ-
ous studies usually excluded patients with pneumonia, 
we chose patients treated for pneumonia.
Many patients with neuromuscular disease, have re-
spiratory muscle weakness that leads to declined lung 
compliance. Consistent increase in PCF may be ex-
plained as increase in compliance of the lung and chest 
wall. According to previous studies, lung compliance and 
the capacity for breathing increased for 3 hours, upon 
MI-E application in patients with kyphoscoliosis or ALS 
[15,16]. We can assume that the forced vital capacity and 
PCF, are increased temporarily by increased lung compli-
ance. Furthermore, increased cough flow may be due to 
temporary conditioning, and strengthening effects on the 
respiratory muscle of the stretching exercise [17]. Stretch-
ing of respiratory muscles facilitates actin-myosin inter-
action, and strengthens respiratory muscles. Reduced 
airway resistance after removal of respiratory secretions, 
is also a probable mechanism, and has been proven in 
many previous studies.
This study has limitations. We assumed that the 15 min-
utes time point reflects the short-term effect of MI-E and 
45 minutes reflect the lasting effect. However, 45 minutes 
is not sufficient time to reflect lasting effect of treatment. 
Maximum insufflation capacity, maximal expiratory pres-
sure, and maximal inspiratory pressure were checked 
only at baseline, and only PCF and APCF were checked 
during follow-up. It is also a limitation that the mecha-
nism of increasing PCF, was not definitively explained. 
A longer-termed and detailed evaluation is needed to 
explain lasting effect of this treatment. Severity, type, and 
disease course of pneumonia, as well as patient status at 
the moment of evaluation during the hospital stay, were 
not considered in detail, all of which could have an effect 
on response to treatment with MI-E. 
In addition, the training effect may also be considered. 
It would be difficult to explain the consistent increase in 
PCF after an intervention, as all subjects were repeatedly 
evaluated in PCF and APCF consecutively during follow-
up periods also. Therefore, the training effect should be 
considered, as repetitive instructions also increase sub-
jects’ compliance with using MI-E.
As this was not a blinded or randomized control study, 
we could not conclude whether increased PCF affect 
the course of pneumonia. The effect of increased PCF in 
patients with neuromuscular disease and pneumonia 
could have been more definitely evaluated, if another 
group such as patients with pneumonia not using MI-E 
or patients without pneumonia was compared. Further 
case–control studies involving a large group of subjects 
and more detailed evaluation, are needed to explain the 
accurate mechanism for these effects.
In conclusion, increased ability to expectorate sputum 
was confirmed after using MI-E, which persisted for at 
least 45 minutes after therapy. MI-E is a useful device for 
patients with neuromuscular disease and pneumonia, 
not only as the best way to manage secretion, but also as 
an intervention to maintaining coughing ability.
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